Published • loading... • Updated
Alnylam, Inceptive Ink AI Deal Potentially Worth $2B
The three-year pact pairs Inceptive’s foundation models with Alnylam’s RNAi platform to speed siRNA design and includes milestone payments.
- On Wednesday, Alnylam Pharmaceuticals and Inceptive Nucleics announced a strategic collaboration worth up to $2 billion to accelerate RNA interference drug discovery using artificial intelligence.
- Inceptive CEO Jakob Uszkoreit noted that 'most drug design still works through a process of trial and error, testing thousands of molecules and hoping something sticks,' a limitation the partnership addresses.
- Alnylam will pay $30 million upfront in cash and equity, gaining access to Inceptive's AI expertise and talent including co-founder Uszkoreit, who co-invented the Transformer architecture underlying ChatGPT.
- CEO Yvonne Greenstreet, M.D., stated the company is 'thrilled to partner with Inceptive to push the boundaries' of RNAi medicine, supporting Alnylam's 2030 strategy for pipeline expansion.
- Inceptive, founded in 2021, specializes in sequence-based medicine design including siRNA and peptides, bolstering Alnylam's global reach which currently spans more than 70 countries.
Insights by Ground AI
11 Articles
11 Articles
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Alnylam Pharmaceuticals (
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock is up on Thursday after the company announced a strategic collaboration with Inceptive Nucleics, valued at up to $2 billion. The partnership aims to enhance the discovery of RNA interference (RNAi) therapeutics by integrating Alnylam’s RNAi platform with Inceptive’s AI expertise, potentially accelerating timelines for innovative drug designs. Alnylam aims to accelerate the discovery of novel RNAi…
·New York, United States
Read Full Article
Las Vegas Sun+2 Reposted by 2 other sources
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
None
·Las Vegas, United States
Read Full Article
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
·New York, United States
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left1Leaning Right1Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 17%
C 67%
R 16%
Factuality
To view factuality data please Upgrade to Premium
